Review



anti pd 1 αpd 1 monoclonal antibody  (Bio X Cell)


Bioz Verified Symbol Bio X Cell is a verified supplier
Bioz Manufacturer Symbol Bio X Cell manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 99
      Buy from Supplier

    Structured Review

    Bio X Cell anti pd 1 αpd 1 monoclonal antibody
    DNA prime-peptide boost immunization strategy against endogenous neoepitopes confers therapeutic protection in MC38 tumor model. C57BL/6 mice were intradermally challenged with MC38 cells and 3 d later were intradermally immunized with a DNA vaccine encoding Adpgk (299–307) and p15E (134–141) neoepitopes. Seven days later mice received peptide boost immunization. Additional groups included mice treated with αPD-1 monotherapy or a combination of DNA/peptide vaccination and αPD-1. αPD-1 monoclonal antibody was administered intraperitoneally at 200 µg per dose on days 12, 15, and 18 post-tumor challenge. Unvaccinated and DNA immunized mice were used as controls. (a–b) Individual tumor growth (a) and cumulative event curve (tumor rejection) (b). (c–d) CD8 + T-cell responses against neoepitopes were evaluated in blood 7 d after the last vaccination by flow cytometry. Peripheral blood cells were stimulated ex vivo with cognate peptides, followed by intracellular cytokine staining. (c) Representative plots showing the expression of TNF- α and IFN- γ in total CD8 + T cells. Unstimulated control (upper panels), Adpgk (299–307) peptide (middle panels) and p15E (134–141) peptide (bottom) samples are shown. (d) Quantification of IFN-γ + Adpgk (299–307) - and p15E (134–141) -specific CD8 + T cells in peptide stimulated samples. (e) Representative flow cytometry plots showing co-expression of IFN- γ and TNF- α (left), and granzyme B (GZB, right) in IFN-γ⁺ Adpgk (299–307)- and p15E (134–141) -specific CD8⁺ T cells from peptide-stimulated samples of DNA/peptide-vaccinated mice. Histograms (right panels) depict GZB expression in IFN-γ⁻ (gray) and IFN-γ⁺ (blue) CD8⁺ T cells from a representative DNA prime-peptide boost vaccinated mouse. Data in (a–b) is from four independent experiments for Control ( n = 21), DNA ( n = 5) and DNA/Peptide ( n = 20) and two independent experiments for αPD-1 ( n = 10) and DNA/Peptide + αPD-1 ( n = 8). Data in (c-d) is from seven independent experiments for control ( n = 19), DNA ( n = 10) and DNA/Peptide ( n = 23) and two independent experiments for αPD-1 ( n = 10) and DNA/Peptide + αPD-1 ( n = 10). * p < 0.05, ** p < 0.01 by Mantel‒Cox test in (b). *** p < 0.001, **** p < 0.0001 by Kruskal-Wallis unpaired test.
    Anti Pd 1 αpd 1 Monoclonal Antibody, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 99/100, based on 1103 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/%CE%B1pd+1+antibody/pmc12802984-56-0-6?v=Bio+X+Cell
    Average 99 stars, based on 1103 article reviews
    anti pd 1 αpd 1 monoclonal antibody - by Bioz Stars, 2026-06
    99/100 stars

    Images

    1) Product Images from "DNA prime and peptide boost immunization elicits robust neoantigen-specific CD8 + T cell responses and therapeutic protection in mouse tumor models"

    Article Title: DNA prime and peptide boost immunization elicits robust neoantigen-specific CD8 + T cell responses and therapeutic protection in mouse tumor models

    Journal: Oncoimmunology

    doi: 10.1080/2162402X.2025.2606497

    DNA prime-peptide boost immunization strategy against endogenous neoepitopes confers therapeutic protection in MC38 tumor model. C57BL/6 mice were intradermally challenged with MC38 cells and 3 d later were intradermally immunized with a DNA vaccine encoding Adpgk (299–307) and p15E (134–141) neoepitopes. Seven days later mice received peptide boost immunization. Additional groups included mice treated with αPD-1 monotherapy or a combination of DNA/peptide vaccination and αPD-1. αPD-1 monoclonal antibody was administered intraperitoneally at 200 µg per dose on days 12, 15, and 18 post-tumor challenge. Unvaccinated and DNA immunized mice were used as controls. (a–b) Individual tumor growth (a) and cumulative event curve (tumor rejection) (b). (c–d) CD8 + T-cell responses against neoepitopes were evaluated in blood 7 d after the last vaccination by flow cytometry. Peripheral blood cells were stimulated ex vivo with cognate peptides, followed by intracellular cytokine staining. (c) Representative plots showing the expression of TNF- α and IFN- γ in total CD8 + T cells. Unstimulated control (upper panels), Adpgk (299–307) peptide (middle panels) and p15E (134–141) peptide (bottom) samples are shown. (d) Quantification of IFN-γ + Adpgk (299–307) - and p15E (134–141) -specific CD8 + T cells in peptide stimulated samples. (e) Representative flow cytometry plots showing co-expression of IFN- γ and TNF- α (left), and granzyme B (GZB, right) in IFN-γ⁺ Adpgk (299–307)- and p15E (134–141) -specific CD8⁺ T cells from peptide-stimulated samples of DNA/peptide-vaccinated mice. Histograms (right panels) depict GZB expression in IFN-γ⁻ (gray) and IFN-γ⁺ (blue) CD8⁺ T cells from a representative DNA prime-peptide boost vaccinated mouse. Data in (a–b) is from four independent experiments for Control ( n = 21), DNA ( n = 5) and DNA/Peptide ( n = 20) and two independent experiments for αPD-1 ( n = 10) and DNA/Peptide + αPD-1 ( n = 8). Data in (c-d) is from seven independent experiments for control ( n = 19), DNA ( n = 10) and DNA/Peptide ( n = 23) and two independent experiments for αPD-1 ( n = 10) and DNA/Peptide + αPD-1 ( n = 10). * p < 0.05, ** p < 0.01 by Mantel‒Cox test in (b). *** p < 0.001, **** p < 0.0001 by Kruskal-Wallis unpaired test.
    Figure Legend Snippet: DNA prime-peptide boost immunization strategy against endogenous neoepitopes confers therapeutic protection in MC38 tumor model. C57BL/6 mice were intradermally challenged with MC38 cells and 3 d later were intradermally immunized with a DNA vaccine encoding Adpgk (299–307) and p15E (134–141) neoepitopes. Seven days later mice received peptide boost immunization. Additional groups included mice treated with αPD-1 monotherapy or a combination of DNA/peptide vaccination and αPD-1. αPD-1 monoclonal antibody was administered intraperitoneally at 200 µg per dose on days 12, 15, and 18 post-tumor challenge. Unvaccinated and DNA immunized mice were used as controls. (a–b) Individual tumor growth (a) and cumulative event curve (tumor rejection) (b). (c–d) CD8 + T-cell responses against neoepitopes were evaluated in blood 7 d after the last vaccination by flow cytometry. Peripheral blood cells were stimulated ex vivo with cognate peptides, followed by intracellular cytokine staining. (c) Representative plots showing the expression of TNF- α and IFN- γ in total CD8 + T cells. Unstimulated control (upper panels), Adpgk (299–307) peptide (middle panels) and p15E (134–141) peptide (bottom) samples are shown. (d) Quantification of IFN-γ + Adpgk (299–307) - and p15E (134–141) -specific CD8 + T cells in peptide stimulated samples. (e) Representative flow cytometry plots showing co-expression of IFN- γ and TNF- α (left), and granzyme B (GZB, right) in IFN-γ⁺ Adpgk (299–307)- and p15E (134–141) -specific CD8⁺ T cells from peptide-stimulated samples of DNA/peptide-vaccinated mice. Histograms (right panels) depict GZB expression in IFN-γ⁻ (gray) and IFN-γ⁺ (blue) CD8⁺ T cells from a representative DNA prime-peptide boost vaccinated mouse. Data in (a–b) is from four independent experiments for Control ( n = 21), DNA ( n = 5) and DNA/Peptide ( n = 20) and two independent experiments for αPD-1 ( n = 10) and DNA/Peptide + αPD-1 ( n = 8). Data in (c-d) is from seven independent experiments for control ( n = 19), DNA ( n = 10) and DNA/Peptide ( n = 23) and two independent experiments for αPD-1 ( n = 10) and DNA/Peptide + αPD-1 ( n = 10). * p < 0.05, ** p < 0.01 by Mantel‒Cox test in (b). *** p < 0.001, **** p < 0.0001 by Kruskal-Wallis unpaired test.

    Techniques Used: Flow Cytometry, Ex Vivo, Staining, Expressing, Control



    Similar Products

    αpd 1  (MedChemExpress)
    95
    MedChemExpress αpd 1
    αpd 1, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/%CE%B1pd+1+antibody/pm41608639-77-4-6?v=MedChemExpress
    Average 95 stars, based on 1 article reviews
    αpd 1 - by Bioz Stars, 2026-06
    95/100 stars
    		  Buy from Supplier
    anti pd 1 αpd 1 monoclonal antibody  (Bio X Cell)
    99
    Bio X Cell anti pd 1 αpd 1 monoclonal antibody
    DNA prime-peptide boost immunization strategy against endogenous neoepitopes confers therapeutic protection in MC38 tumor model. C57BL/6 mice were intradermally challenged with MC38 cells and 3 d later were intradermally immunized with a DNA vaccine encoding Adpgk (299–307) and p15E (134–141) neoepitopes. Seven days later mice received peptide boost immunization. Additional groups included mice treated with αPD-1 monotherapy or a combination of DNA/peptide vaccination and αPD-1. αPD-1 monoclonal antibody was administered intraperitoneally at 200 µg per dose on days 12, 15, and 18 post-tumor challenge. Unvaccinated and DNA immunized mice were used as controls. (a–b) Individual tumor growth (a) and cumulative event curve (tumor rejection) (b). (c–d) CD8 + T-cell responses against neoepitopes were evaluated in blood 7 d after the last vaccination by flow cytometry. Peripheral blood cells were stimulated ex vivo with cognate peptides, followed by intracellular cytokine staining. (c) Representative plots showing the expression of TNF- α and IFN- γ in total CD8 + T cells. Unstimulated control (upper panels), Adpgk (299–307) peptide (middle panels) and p15E (134–141) peptide (bottom) samples are shown. (d) Quantification of IFN-γ + Adpgk (299–307) - and p15E (134–141) -specific CD8 + T cells in peptide stimulated samples. (e) Representative flow cytometry plots showing co-expression of IFN- γ and TNF- α (left), and granzyme B (GZB, right) in IFN-γ⁺ Adpgk (299–307)- and p15E (134–141) -specific CD8⁺ T cells from peptide-stimulated samples of DNA/peptide-vaccinated mice. Histograms (right panels) depict GZB expression in IFN-γ⁻ (gray) and IFN-γ⁺ (blue) CD8⁺ T cells from a representative DNA prime-peptide boost vaccinated mouse. Data in (a–b) is from four independent experiments for Control ( n = 21), DNA ( n = 5) and DNA/Peptide ( n = 20) and two independent experiments for αPD-1 ( n = 10) and DNA/Peptide + αPD-1 ( n = 8). Data in (c-d) is from seven independent experiments for control ( n = 19), DNA ( n = 10) and DNA/Peptide ( n = 23) and two independent experiments for αPD-1 ( n = 10) and DNA/Peptide + αPD-1 ( n = 10). * p < 0.05, ** p < 0.01 by Mantel‒Cox test in (b). *** p < 0.001, **** p < 0.0001 by Kruskal-Wallis unpaired test.
    Anti Pd 1 αpd 1 Monoclonal Antibody, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/%CE%B1pd+1+antibody/pmc12802984-56-0-6?v=Bio+X+Cell
    Average 99 stars, based on 1 article reviews
    anti pd 1 αpd 1 monoclonal antibody - by Bioz Stars, 2026-06
    99/100 stars
    		  Buy from Supplier
    αpd 1 antibody  (Bio X Cell)
    99
    Bio X Cell αpd 1 antibody
    DNA prime-peptide boost immunization strategy against endogenous neoepitopes confers therapeutic protection in MC38 tumor model. C57BL/6 mice were intradermally challenged with MC38 cells and 3 d later were intradermally immunized with a DNA vaccine encoding Adpgk (299–307) and p15E (134–141) neoepitopes. Seven days later mice received peptide boost immunization. Additional groups included mice treated with αPD-1 monotherapy or a combination of DNA/peptide vaccination and αPD-1. αPD-1 monoclonal antibody was administered intraperitoneally at 200 µg per dose on days 12, 15, and 18 post-tumor challenge. Unvaccinated and DNA immunized mice were used as controls. (a–b) Individual tumor growth (a) and cumulative event curve (tumor rejection) (b). (c–d) CD8 + T-cell responses against neoepitopes were evaluated in blood 7 d after the last vaccination by flow cytometry. Peripheral blood cells were stimulated ex vivo with cognate peptides, followed by intracellular cytokine staining. (c) Representative plots showing the expression of TNF- α and IFN- γ in total CD8 + T cells. Unstimulated control (upper panels), Adpgk (299–307) peptide (middle panels) and p15E (134–141) peptide (bottom) samples are shown. (d) Quantification of IFN-γ + Adpgk (299–307) - and p15E (134–141) -specific CD8 + T cells in peptide stimulated samples. (e) Representative flow cytometry plots showing co-expression of IFN- γ and TNF- α (left), and granzyme B (GZB, right) in IFN-γ⁺ Adpgk (299–307)- and p15E (134–141) -specific CD8⁺ T cells from peptide-stimulated samples of DNA/peptide-vaccinated mice. Histograms (right panels) depict GZB expression in IFN-γ⁻ (gray) and IFN-γ⁺ (blue) CD8⁺ T cells from a representative DNA prime-peptide boost vaccinated mouse. Data in (a–b) is from four independent experiments for Control ( n = 21), DNA ( n = 5) and DNA/Peptide ( n = 20) and two independent experiments for αPD-1 ( n = 10) and DNA/Peptide + αPD-1 ( n = 8). Data in (c-d) is from seven independent experiments for control ( n = 19), DNA ( n = 10) and DNA/Peptide ( n = 23) and two independent experiments for αPD-1 ( n = 10) and DNA/Peptide + αPD-1 ( n = 10). * p < 0.05, ** p < 0.01 by Mantel‒Cox test in (b). *** p < 0.001, **** p < 0.0001 by Kruskal-Wallis unpaired test.
    αpd 1 Antibody, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/%CE%B1pd+1+antibody/us12503473-335-25-28?v=Bio+X+Cell
    Average 99 stars, based on 1 article reviews
    αpd 1 antibody - by Bioz Stars, 2026-06
    99/100 stars
    		  Buy from Supplier
    death 1 inhibitor antibody αpd 1  (Amyjet Scientific Inc)
    86
    Amyjet Scientific Inc death 1 inhibitor antibody αpd 1
    DNA prime-peptide boost immunization strategy against endogenous neoepitopes confers therapeutic protection in MC38 tumor model. C57BL/6 mice were intradermally challenged with MC38 cells and 3 d later were intradermally immunized with a DNA vaccine encoding Adpgk (299–307) and p15E (134–141) neoepitopes. Seven days later mice received peptide boost immunization. Additional groups included mice treated with αPD-1 monotherapy or a combination of DNA/peptide vaccination and αPD-1. αPD-1 monoclonal antibody was administered intraperitoneally at 200 µg per dose on days 12, 15, and 18 post-tumor challenge. Unvaccinated and DNA immunized mice were used as controls. (a–b) Individual tumor growth (a) and cumulative event curve (tumor rejection) (b). (c–d) CD8 + T-cell responses against neoepitopes were evaluated in blood 7 d after the last vaccination by flow cytometry. Peripheral blood cells were stimulated ex vivo with cognate peptides, followed by intracellular cytokine staining. (c) Representative plots showing the expression of TNF- α and IFN- γ in total CD8 + T cells. Unstimulated control (upper panels), Adpgk (299–307) peptide (middle panels) and p15E (134–141) peptide (bottom) samples are shown. (d) Quantification of IFN-γ + Adpgk (299–307) - and p15E (134–141) -specific CD8 + T cells in peptide stimulated samples. (e) Representative flow cytometry plots showing co-expression of IFN- γ and TNF- α (left), and granzyme B (GZB, right) in IFN-γ⁺ Adpgk (299–307)- and p15E (134–141) -specific CD8⁺ T cells from peptide-stimulated samples of DNA/peptide-vaccinated mice. Histograms (right panels) depict GZB expression in IFN-γ⁻ (gray) and IFN-γ⁺ (blue) CD8⁺ T cells from a representative DNA prime-peptide boost vaccinated mouse. Data in (a–b) is from four independent experiments for Control ( n = 21), DNA ( n = 5) and DNA/Peptide ( n = 20) and two independent experiments for αPD-1 ( n = 10) and DNA/Peptide + αPD-1 ( n = 8). Data in (c-d) is from seven independent experiments for control ( n = 19), DNA ( n = 10) and DNA/Peptide ( n = 23) and two independent experiments for αPD-1 ( n = 10) and DNA/Peptide + αPD-1 ( n = 10). * p < 0.05, ** p < 0.01 by Mantel‒Cox test in (b). *** p < 0.001, **** p < 0.0001 by Kruskal-Wallis unpaired test.
    Death 1 Inhibitor Antibody αpd 1, supplied by Amyjet Scientific Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/%CE%B1pd+1+antibody/pmc12686171-77-11-16?v=Amyjet+Scientific+Inc
    Average 86 stars, based on 1 article reviews
    death 1 inhibitor antibody αpd 1 - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier
    αpd-1 antibody  (Bio X Cell)
    90
    Bio X Cell αpd-1 antibody
    DNA prime-peptide boost immunization strategy against endogenous neoepitopes confers therapeutic protection in MC38 tumor model. C57BL/6 mice were intradermally challenged with MC38 cells and 3 d later were intradermally immunized with a DNA vaccine encoding Adpgk (299–307) and p15E (134–141) neoepitopes. Seven days later mice received peptide boost immunization. Additional groups included mice treated with αPD-1 monotherapy or a combination of DNA/peptide vaccination and αPD-1. αPD-1 monoclonal antibody was administered intraperitoneally at 200 µg per dose on days 12, 15, and 18 post-tumor challenge. Unvaccinated and DNA immunized mice were used as controls. (a–b) Individual tumor growth (a) and cumulative event curve (tumor rejection) (b). (c–d) CD8 + T-cell responses against neoepitopes were evaluated in blood 7 d after the last vaccination by flow cytometry. Peripheral blood cells were stimulated ex vivo with cognate peptides, followed by intracellular cytokine staining. (c) Representative plots showing the expression of TNF- α and IFN- γ in total CD8 + T cells. Unstimulated control (upper panels), Adpgk (299–307) peptide (middle panels) and p15E (134–141) peptide (bottom) samples are shown. (d) Quantification of IFN-γ + Adpgk (299–307) - and p15E (134–141) -specific CD8 + T cells in peptide stimulated samples. (e) Representative flow cytometry plots showing co-expression of IFN- γ and TNF- α (left), and granzyme B (GZB, right) in IFN-γ⁺ Adpgk (299–307)- and p15E (134–141) -specific CD8⁺ T cells from peptide-stimulated samples of DNA/peptide-vaccinated mice. Histograms (right panels) depict GZB expression in IFN-γ⁻ (gray) and IFN-γ⁺ (blue) CD8⁺ T cells from a representative DNA prime-peptide boost vaccinated mouse. Data in (a–b) is from four independent experiments for Control ( n = 21), DNA ( n = 5) and DNA/Peptide ( n = 20) and two independent experiments for αPD-1 ( n = 10) and DNA/Peptide + αPD-1 ( n = 8). Data in (c-d) is from seven independent experiments for control ( n = 19), DNA ( n = 10) and DNA/Peptide ( n = 23) and two independent experiments for αPD-1 ( n = 10) and DNA/Peptide + αPD-1 ( n = 10). * p < 0.05, ** p < 0.01 by Mantel‒Cox test in (b). *** p < 0.001, **** p < 0.0001 by Kruskal-Wallis unpaired test.
    αpd 1 Antibody, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/%CE%B1pd+1+antibody/us12365901-176-10-21?v=Bio+X+Cell
    Average 90 stars, based on 1 article reviews
    αpd-1 antibody - by Bioz Stars, 2026-06
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    DNA prime-peptide boost immunization strategy against endogenous neoepitopes confers therapeutic protection in MC38 tumor model. C57BL/6 mice were intradermally challenged with MC38 cells and 3 d later were intradermally immunized with a DNA vaccine encoding Adpgk (299–307) and p15E (134–141) neoepitopes. Seven days later mice received peptide boost immunization. Additional groups included mice treated with αPD-1 monotherapy or a combination of DNA/peptide vaccination and αPD-1. αPD-1 monoclonal antibody was administered intraperitoneally at 200 µg per dose on days 12, 15, and 18 post-tumor challenge. Unvaccinated and DNA immunized mice were used as controls. (a–b) Individual tumor growth (a) and cumulative event curve (tumor rejection) (b). (c–d) CD8 + T-cell responses against neoepitopes were evaluated in blood 7 d after the last vaccination by flow cytometry. Peripheral blood cells were stimulated ex vivo with cognate peptides, followed by intracellular cytokine staining. (c) Representative plots showing the expression of TNF- α and IFN- γ in total CD8 + T cells. Unstimulated control (upper panels), Adpgk (299–307) peptide (middle panels) and p15E (134–141) peptide (bottom) samples are shown. (d) Quantification of IFN-γ + Adpgk (299–307) - and p15E (134–141) -specific CD8 + T cells in peptide stimulated samples. (e) Representative flow cytometry plots showing co-expression of IFN- γ and TNF- α (left), and granzyme B (GZB, right) in IFN-γ⁺ Adpgk (299–307)- and p15E (134–141) -specific CD8⁺ T cells from peptide-stimulated samples of DNA/peptide-vaccinated mice. Histograms (right panels) depict GZB expression in IFN-γ⁻ (gray) and IFN-γ⁺ (blue) CD8⁺ T cells from a representative DNA prime-peptide boost vaccinated mouse. Data in (a–b) is from four independent experiments for Control ( n = 21), DNA ( n = 5) and DNA/Peptide ( n = 20) and two independent experiments for αPD-1 ( n = 10) and DNA/Peptide + αPD-1 ( n = 8). Data in (c-d) is from seven independent experiments for control ( n = 19), DNA ( n = 10) and DNA/Peptide ( n = 23) and two independent experiments for αPD-1 ( n = 10) and DNA/Peptide + αPD-1 ( n = 10). * p < 0.05, ** p < 0.01 by Mantel‒Cox test in (b). *** p < 0.001, **** p < 0.0001 by Kruskal-Wallis unpaired test.

    Journal: Oncoimmunology

    Article Title: DNA prime and peptide boost immunization elicits robust neoantigen-specific CD8 + T cell responses and therapeutic protection in mouse tumor models

    doi: 10.1080/2162402X.2025.2606497

    Figure Lengend Snippet: DNA prime-peptide boost immunization strategy against endogenous neoepitopes confers therapeutic protection in MC38 tumor model. C57BL/6 mice were intradermally challenged with MC38 cells and 3 d later were intradermally immunized with a DNA vaccine encoding Adpgk (299–307) and p15E (134–141) neoepitopes. Seven days later mice received peptide boost immunization. Additional groups included mice treated with αPD-1 monotherapy or a combination of DNA/peptide vaccination and αPD-1. αPD-1 monoclonal antibody was administered intraperitoneally at 200 µg per dose on days 12, 15, and 18 post-tumor challenge. Unvaccinated and DNA immunized mice were used as controls. (a–b) Individual tumor growth (a) and cumulative event curve (tumor rejection) (b). (c–d) CD8 + T-cell responses against neoepitopes were evaluated in blood 7 d after the last vaccination by flow cytometry. Peripheral blood cells were stimulated ex vivo with cognate peptides, followed by intracellular cytokine staining. (c) Representative plots showing the expression of TNF- α and IFN- γ in total CD8 + T cells. Unstimulated control (upper panels), Adpgk (299–307) peptide (middle panels) and p15E (134–141) peptide (bottom) samples are shown. (d) Quantification of IFN-γ + Adpgk (299–307) - and p15E (134–141) -specific CD8 + T cells in peptide stimulated samples. (e) Representative flow cytometry plots showing co-expression of IFN- γ and TNF- α (left), and granzyme B (GZB, right) in IFN-γ⁺ Adpgk (299–307)- and p15E (134–141) -specific CD8⁺ T cells from peptide-stimulated samples of DNA/peptide-vaccinated mice. Histograms (right panels) depict GZB expression in IFN-γ⁻ (gray) and IFN-γ⁺ (blue) CD8⁺ T cells from a representative DNA prime-peptide boost vaccinated mouse. Data in (a–b) is from four independent experiments for Control ( n = 21), DNA ( n = 5) and DNA/Peptide ( n = 20) and two independent experiments for αPD-1 ( n = 10) and DNA/Peptide + αPD-1 ( n = 8). Data in (c-d) is from seven independent experiments for control ( n = 19), DNA ( n = 10) and DNA/Peptide ( n = 23) and two independent experiments for αPD-1 ( n = 10) and DNA/Peptide + αPD-1 ( n = 10). * p < 0.05, ** p < 0.01 by Mantel‒Cox test in (b). *** p < 0.001, **** p < 0.0001 by Kruskal-Wallis unpaired test.

    Article Snippet: Anti–PD-1 (αPD-1) monoclonal antibody (clone RMP1-14, BioXCell, catalog #BE0146) was administered at a dose of 200 μg per mouse on days 12, 15, and 18 after tumor challenge. αPD-1 therapy was evaluated both as monotherapy and in combination with the DNA prime–peptide boost immunization regimen described above.

    Techniques: Flow Cytometry, Ex Vivo, Staining, Expressing, Control